Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Fluorouracil
Overview
What is Adrucil?
Adrucil (fluorouracil injection USP), a nucleoside metabolic inhibitor, is a sterile, nonpyrogenic injectable solution for intravenous administration. Each 10 mL contains 500 mg fluorouracil, USP; pH is adjusted to 8.6 to 9.4 with sodium hydroxide.
Chemically, fluorouracil, USP, a fluorinated pyrimidine, is 5-fluoro-2,4 (1,3)-pyrimidinedione. It is a white to practically white crystalline powder which is sparingly soluble in water. The structural formula is:
CHFNOM.W. 130.08
What does Adrucil look like?
What are the available doses of Adrucil?
Injection:
What should I talk to my health care provider before I take Adrucil?
How should I use Adrucil?
Adrucil (fluorouracil injection) is indicated for the treatment of patients with:
Adrucil is recommended for administration either as an intravenous bolus or as an intravenous infusion. Individualize the dose and dosing schedule of fluorouracil based on tumor type, the specific regimen administered, disease state, response to treatment, and patient risk factors.
What interacts with Adrucil?
Sorry No Records found
What are the warnings of Adrucil?
Sorry No Records found
What are the precautions of Adrucil?
Sorry No Records found
What are the side effects of Adrucil?
Sorry No records found
What should I look out for while using Adrucil?
None.
What might happen if I take too much Adrucil?
Administer uridine triacetate within 96 hours following the end of fluorouracil infusion for management of fluorouracil overdose.
How should I store and handle Adrucil?
Store at 20°–25°C (68°–77°F); excursions permitted to 15°–30°C (59°–86°F). [See USP Controlled Room Temperature].Zonisamide Capsules, USP are available containing 25 mg of zonisamide, USP.The 25 mg capsule is a violet opaque cap and lavender opaque body, hard-shell gelatin capsule filled with white to off-white powder. The capsule is axially printed with over in black ink on both the cap and body. They are available as follows: bottles of 14 and 30 capsulesStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from moisture and light.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Zonisamide Capsules, USP are available containing 25 mg of zonisamide, USP.The 25 mg capsule is a violet opaque cap and lavender opaque body, hard-shell gelatin capsule filled with white to off-white powder. The capsule is axially printed with over in black ink on both the cap and body. They are available as follows: bottles of 14 and 30 capsulesStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from moisture and light.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Zonisamide Capsules, USP are available containing 25 mg of zonisamide, USP.The 25 mg capsule is a violet opaque cap and lavender opaque body, hard-shell gelatin capsule filled with white to off-white powder. The capsule is axially printed with over in black ink on both the cap and body. They are available as follows: bottles of 14 and 30 capsulesStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from moisture and light.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Zonisamide Capsules, USP are available containing 25 mg of zonisamide, USP.The 25 mg capsule is a violet opaque cap and lavender opaque body, hard-shell gelatin capsule filled with white to off-white powder. The capsule is axially printed with over in black ink on both the cap and body. They are available as follows: bottles of 14 and 30 capsulesStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from moisture and light.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Zonisamide Capsules, USP are available containing 25 mg of zonisamide, USP.The 25 mg capsule is a violet opaque cap and lavender opaque body, hard-shell gelatin capsule filled with white to off-white powder. The capsule is axially printed with over in black ink on both the cap and body. They are available as follows: bottles of 14 and 30 capsulesStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from moisture and light.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Zonisamide Capsules, USP are available containing 25 mg of zonisamide, USP.The 25 mg capsule is a violet opaque cap and lavender opaque body, hard-shell gelatin capsule filled with white to off-white powder. The capsule is axially printed with over in black ink on both the cap and body. They are available as follows: bottles of 14 and 30 capsulesStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from moisture and light.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Zonisamide Capsules, USP are available containing 25 mg of zonisamide, USP.The 25 mg capsule is a violet opaque cap and lavender opaque body, hard-shell gelatin capsule filled with white to off-white powder. The capsule is axially printed with over in black ink on both the cap and body. They are available as follows: bottles of 14 and 30 capsulesStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from moisture and light.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Fluorouracil is a nucleoside metabolic inhibitor that interferes with the synthesis of deoxyribonucleic acid (DNA) and to a lesser extent inhibits the formation of ribonucleic acid (RNA); these affect rapidly growing cells and may lead to cell death. Fluorouracil is converted to three main active metabolites: 5-fluoro-2′-deoxyuridine-5′-monophosphate (FdUMP), 5-fluorouridine-5′-triphosphate (FUTP) and 5-fluoro-2′-deoxyuridine-5′-triphosphate (FdUTP). These metabolites have several effects including the inhibition of thymidylate synthase by FdUMP, incorporation of FUTP into RNA and incorporation of FdUTP into DNA.
Non-Clinical Toxicology
None.Food: Isoniazid should not be administered with food. Studies have shown that the bioavailability of isoniazid is reduced significantly when administered with food.
Acetaminophen: A report of severe acetaminophen toxicity was reported in a patient receiving isoniazid. It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed. However, current evidence suggests that isoniazid does induce P-450IIE1, a mixed-function oxidase enzyme that appears to generate the toxic metabolites, in the liver. Furthermore it has been proposed that isoniazid resulted in induction of P-450IIE1 in the patient's liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites. Studies have demonstrated that pretreatment with isoniazid potentiates acetaminophen hepatotoxicity in rats.
Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels. Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.
Ketoconazole: Potential interaction of ketoconazole and isoniazid may exist. When ketoconazole is given in combination with isoniazid and rifampin the AUC of ketoconazole is decreased by as much as 88% after 5 months of concurrent isoniazid and rifampin therapy.
Phenytoin: Isoniazid may increase serum levels of phenytoin. To avoid phenytoin intoxication, appropriate adjustment of the anticonvulsant should be made.
Theophylline: A recent study has shown that concomitant administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid. Since the therapeutic range of theophylline is narrow, theophylline serum levels should be monitored closely, and appropriate dosage adjustments of theophylline should be made.
Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co-administered with isoniazid. Plasma valproate concentration should be monitored when isoniazid and valproate are co-administered, and appropriate dosage adjustments of valproate should be made.
Based on postmarketing reports, patients with certain homozygous or certain compound heterozygous mutations in the DPD gene that result in complete or near complete absence of DPD activity are at increased risk for acute early-onset of toxicity and severe, life-threatening, or fatal adverse reactions caused by fluorouracil (e.g., mucositis, diarrhea, neutropenia, and neurotoxicity). Patients with partial DPD activity may also have increased risk of severe, life-threatening, or fatal adverse reactions caused by fluorouracil.
Withhold or permanently discontinue fluorouracil based on clinical assessment of the onset, duration and severity of the observed toxicities in patients with evidence of acute early-onset or unusually severe toxicity, which may indicate near complete or total absence of DPD activity. No fluorouracil dose has been proven safe for patients with complete absence of DPD activity. There is insufficient data to recommend a specific dose in patients with partial DPD activity as measured by any specific test.
The following adverse reactions are discussed in more detail in other sections of the labeling:
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
516Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).